Doxil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Doxil

Quick Facts

Property Description
Active ingredient Doxorubicin hydrochloride (encapsulated)
Form Sterile suspension for intravenous infusion
Pharmacological class Antineoplastic agent, Anthracycline
General purpose Systemic cancer treatment (delivery optimization)
Origin Synthetic formulation (nanomedicine)

What Type of Medicine is Pegylated Liposomal Doxorubicin? (Doxil Classification)

Pegylated Liposomal Doxorubicin (PLD), marketed internationally under names including Doxil and Caelyx, is a specialized, prescription-only medicine. It is classified as an antineoplastic agent and a cytotoxic anthracycline antibiotic, a class clinically recognized for its essential role in many cancer protocols. The active compound is Doxorubicin hydrochloride. While the original doxorubicin substance derives from biological sources, the final Doxil formulation is a sophisticated synthetic product based on nanomedicine principles. This preparation is a single active ingredient product, distinguishing itself from combination therapies used for systemic cancer treatment.

Composition and Unique Liposomal Formulation

This medicine is supplied as a sterile suspension designed for parenteral administration via intravenous infusion. The core differentiator of Doxil is that the Doxorubicin hydrochloride is entirely enclosed within a protective shell called a liposome, functioning as a lipid bilayer vehicle. These specific liposomes undergo pegylation—a coating process that creates a Stealth liposome and establishes the medicine as a novel drug delivery system. This liposomal structure is intended to modify the distribution of the active substance within the body, a feature supported by pharmacological characteristics.

General Therapeutic Goal and Core Purpose

The primary therapeutic goal is to optimize the delivery of the potent cytostatic agent to malignant tissues throughout the body. The unique formulation is designed to enable a prolonged circulation time in the bloodstream. This extended presence allows the formulation to passively accumulate preferentially in areas of fast-growing abnormal tissue via the Enhanced Permeability and Retention (EPR) effect. The formulation's primary objective is to enhance the destructive action of the Doxorubicin on malignant cells by concentrating the drug in the tumor environment.

Regulatory References

  1. NIH: Doxorubicin Information
  2. EMA Caelyx EPAR
  3. Caelyx pegylated liposomal EPAR

What side effects are possible with Doxil?

Possible Side Effects and Safety Information

Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is associated with officially documented adverse reactions classified by frequency and body system in regulatory labels. The profile is characterized by cytotoxic systemic effects and administration-related issues.


Key Regulatory Safety Classifications

Classification Examples of Officially Listed Adverse Reactions
Very Common Myelosuppression (Neutropenia, Anemia, Thrombocytopenia), Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia), Stomatitis/Mucositis, Nausea, Vomiting, Fatigue.
Common Infusion-Related Reactions (those requiring interruption/discontinuation), Hypotension, Peripheral Edema.

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions documented in regulatory sources include potentially irreversible Cardiomyopathy, which is proportional to the cumulative lifetime exposure to anthracyclines. Severe Myelosuppression may lead to life-threatening infections, and the risk of Secondary Malignancies (e.g., Acute Myelogenous Leukemia) is also cited.

Infusion-Related Reactions are officially noted as being most often associated with the first administration. The medicine is contraindicated in patients with known severe hypersensitivity reactions to doxorubicin HCl. Specific safety notes apply to special populations: for instance, its use is restricted in cases of severe hepatic impairment, and AIDS-Related Kaposi's Sarcoma patients may experience more pronounced myelosuppression compared to other oncology patients.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile states that an acute overdosage with pegylated liposomal doxorubicin is expected to result in an exaggeration of the drug’s known toxic effects. No specific antidote for Doxil is documented in the prescribing information.

Documented Overdose Manifestations

System Affected Severe Manifestation
Hematologic Worsened leucopenia and thrombocytopenia (severe myelosuppression).
Cardiovascular Myocardial damage and the risk of Congestive Heart Failure related to elevated cumulative dose.
Mucosal/Skin Exaggerated mucositis and severe forms of Palmar-Plantar Erythrodysesthesia (HFS).

Required Emergency Actions

Immediate medical attention is necessary for the severely myelosuppressed patient and for serious or life-threatening infusion-related reactions.

  • Hospitalisation is a mandatory component of managing acute overdosage.
  • Treatment involves intensive supportive measures such as antibiotics and platelet and granulocyte transfusions.
  • The infusion must be immediately terminated upon signs of a serious infusion reaction, and emergency equipment must be readily available.
  • Mandatory cardiac function monitoring is required due to the risk associated with cumulative dose.

Therapeutic Uses of Doxil

This medicine is commonly used to help manage the systemic burden in situations where patients experience symptoms related to systemic imbalance due to advanced malignancies. The main therapeutic domains involve managing symptoms associated with advanced Ovarian cancer, Multiple Myeloma, and AIDS-Related Kaposi's Sarcoma.


Treating Advanced and Relapsed Cancer

This medication is commonly used as a systemic treatment for certain conditions characterized by periods of heightened symptoms, such as advanced Ovarian cancer following the failure of platinum-based chemotherapy, and Multiple Myeloma after at least one previous therapy, often within a combination regimen. The primary therapeutic benefit may be part of managing symptoms related to active disease and may assist with addressing symptoms related to physical discomfort arising from malignant tissue.


Managing AIDS-Related Kaposi's Sarcoma (KS) Manifestations

Doxil is also applied across domains where additional symptomatic support is needed for patients with advanced AIDS-Related Kaposi's Sarcoma, particularly when previous systemic chemotherapy was either ineffective or poorly tolerated. It is relevant for managing symptoms that interfere with daily functioning and may assist with easing the symptoms related to physical discomfort, such as those manifesting as KS lesions. This approach helps ease associated functional impairment, including chronic swelling (lymphedema), and contributes to improved comfort.


Quick Fact: Supportive Management for KS Symptoms

Aspect Description
Therapeutic Context Used when conditions produce significant symptomatic burden (advanced/relapsed malignancy).
Key Symptoms Managed Symptoms related to physical discomfort (e.g., KS lesions) and symptoms related to systemic imbalance (secondary swelling).
Patient Benefit Contributes to improved comfort and assists with maintaining functional stability.
Severity Relevance Applied in situations involving recurrent or episodic manifestations following prior therapy.

Eligibility and Restrictions for Use

Who Can and Cannot Use Doxil?

Use of Doxil (pegylated liposomal doxorubicin) is strictly governed by regulatory eligibility rules defined by government health authorities.

Absolute Contraindications

Doxil must not be used in patients with a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride or any other component of the formulation.

Age and Established Use

The medicine is approved for the adult patient population, which includes older adults (geriatric patients). However, the safety and effectiveness have not been established in patients less than 18 years of age (pediatric use is not established).

Conditional and Restricted Eligibility

  • Organ Function: Eligibility is conditional on the level of hepatic impairment. Patients with elevated bilirubin must receive a dose reduction. No specific dose modification is typically required for mild to moderate renal impairment.
  • Cardiovascular History: Use is restricted for patients with a history of cardiovascular disease or high prior exposure to anthracyclines, requiring mandatory cardiac monitoring before and during treatment.

Reproductive Status

The medicine is not recommended for use during pregnancy due to the risk of fetal harm. Patients who are breastfeeding must discontinue lactation throughout therapy. Both male and female patients of reproductive potential are required to use effective contraception during and for a specified period following treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the clinically significant interaction patterns for Pegylated Liposomal Doxorubicin as documented in official government regulatory information.


Pharmacodynamic and Cardiotoxicity Risks

Co-administration with or prior use of other anthracyclines or anthracenediones contributes to the total lifetime cumulative dose, which is officially associated with an increased risk of cardiomyopathy. The risk of cardiac dysfunction may also be heightened when used concurrently with other cardiotoxic agents or following prior mediastinal irradiation. This is a critical pharmacodynamic interaction constraint stated in the labeling.


Pharmacokinetic and Metabolic Interactions

Certain medicinal products are documented to modify the drug's systemic exposure. Co-administration with Paclitaxel and Docetaxel results in a pharmacokinetic interaction that increases the plasma concentration (AUC) of the liposomal formulation. Furthermore, the active ingredient's interaction profile involves substances known to affect the conventional doxorubicin metabolism, specifically citing CYP3A4, CYP2D6, and P-glycoprotein (P-gp) inhibitors or inducers.


Administrative and Population Restrictions

Administrative Restriction: Due to documented physicochemical incompatibility, the sterile suspension must not be mixed with any other medicinal product or diluent in the same infusion container or line. Population Consideration: The official label notes that impaired hepatic function alters drug clearance, requiring a specific adjustment in exposure management for this patient population.

Mechanism of Action

The mechanism of Doxil involves multiple molecular pathways targeting the core machinery of proliferating cells, initiated by the active molecule doxorubicin.

Genomic Disruption and Topoisomerase Poisoning

This domain covers the primary molecular interaction where doxorubicin acts as a Topoisomerase II ( TOP2) poison, stabilizing the enzyme-DNA complex and preventing the re-ligation of DNA strand breaks (DSBs). This genomic damage is irreparable and triggers the DNA Damage Response (DDR) pathway, which leads directly to the core physiological consequence of apoptosis and cell cycle arrest.

Oxidative Stress and Accelerated Cytotoxicity

The mechanism includes a secondary pathway where doxorubicin binds to intracellular iron ions, catalyzing the production of highly destructive Reactive Oxygen Species (ROS). This rapid generation of ROS overwhelms the cell's antioxidant defenses, causing widespread damage to organelles like the mitochondria, which accelerates the activation of the programmed cell death pathway and contributes to the overall cytotoxic physiological consequence.

Mechanism Concentration via Nanomedicine

The pegylated liposomal formulation is a sophisticated drug delivery system designed to modify the distribution of the active molecule. It enables the accumulation of the active drug in malignant tissues through the Enhanced Permeability and Retention (EPR) effect, which concentrates the drug's TOP2 poisoning and ROS-generating mechanisms, thereby localizing the cytotoxic physiological effect.

Dosage and Administration Information

How Doxil is Used: Official Administration Guidelines

Doxil (pegylated liposomal doxorubicin) is administered exclusively as an Intravenous (IV) Infusion under the supervision of a physician experienced in cytotoxic agents. It must never be given as an undiluted solution, an intravenous bolus, or by intramuscular/subcutaneous injection. The precise dose and frequency are standardized according to the condition being treated:


Standard Dosing and Schedule

Indication Dose (mg/m^2 Body Surface Area) Frequency Course Duration Principle
Ovarian Cancer 50 mg/m^2 Once every 28 days Until disease progression; minimum 4 courses
AIDS-Related Kaposi's Sarcoma 20 mg/m^2 Once every 21 days Continued as long as treatment is tolerated
Multiple Myeloma 30 mg/m^2 Day 4 of each 21-day cycle Up to 8 cycles in combination with bortezomib

Preparation and Administration Conditions

Before administration, Doxil must be diluted only in 5% Dextrose Injection, USP (D5W). It must not be mixed with other drugs or solutions. The standard infusion duration is 60 minutes. The initial dose should start at a slow rate of 1 mg/min; if well tolerated, the rate is increased to complete the infusion within one hour.

Population and Procedural Rules

Dosage adjustments are mandated for patients with impaired hepatic function (elevated serum bilirubin levels). Conversely, no specific starting dose adjustments are required solely for the elderly population. A critical administration rule is the non-substitution warning: Doxil must not be substituted on a milligram-per-milligram basis with conventional doxorubicin hydrochloride.

Recent Clinical Evidence

Research evidence / Overview of studies for Doxil

Evidence for Advanced or Recurrent Ovarian Cancer

The clinical evaluation of Doxil for advanced or recurrent ovarian cancer primarily used Randomized Controlled Trials (RCTs). These studies were used in research exploring patients whose cancer returned or progressed after they had already received initial platinum-based chemotherapy. Findings describe patterns observed in the studies where measurements of Progression-Free Survival (PFS) were often reported as similar to or, in certain subgroups, comparable to the control treatments utilized in those specific trials. What remains uncertain is the measurement of Overall Survival (OS) in the studies. Research reported that measurements of OS in the trials did not consistently describe a statistical difference when compared to the control treatments across all studied populations.

Evidence for Multiple Myeloma

The foundation of the evidence for Multiple Myeloma comes from Phase III Randomized Controlled Trials (RCTs). Doxil was evaluated in patients with relapsed or refractory disease who had received at least one prior therapy, where research explored its use in combination with bortezomib. Studies reported measurements of Time to Progression (TTP) and PFS that were consistent with the combination approach when compared to bortezomib alone in the patient cohorts studied. Research also describes that the liposomal formulation was studied for its pharmacological profile, and measurements of response were observed. Evidence is limited in that the primary evidence was established only for the specific combination regimen.

Evidence for Advanced AIDS-Related Kaposi's Sarcoma (KS)

Doxil was studied for its use in advanced AIDS-Related Kaposi's Sarcoma, particularly in patients who had either progressed on or were intolerant of prior systemic chemotherapy. Studies monitored the Objective Tumor Response Rate and assessed Sustained Clinical Benefit, which includes outcomes reflecting daily functioning and changes in severe symptoms. Research describes how patients reported their experience regarding functional improvement, which was a key focus of the studies. The research relied heavily on Objective Response Rate as the primary measure for initial evaluation, and follow-up durations were often limited to short-term observation periods.

Research Gaps and What Remains Uncertain

Research provides insight into short-term changes, but there is limited information for long-term outcomes across all indications. The findings concerning a consistent advantage in Overall Survival (OS) are often mixed or uncertain when Doxil is compared to the other treatments utilized in those trials. Comparative evidence is often limited to studies against older regimens and may not fully reflect Doxil's performance against newer therapies that have been approved more recently.

Key Studies & References

  1. Clinical Benefit Sustained in AIDS-Related Kaposi's Sarcoma Patients Treated With Pegylated Liposomal Doxorubicin (Study on Sustained Clinical Benefit)

Frequently Asked Questions (FAQ)

Common questions about Doxil (FAQ)


Q: Is a red or orange color in urine normal after a Doxil infusion?

According to the official product information, it is expected that the urine and other body fluids may appear red or reddish-orange for a period of one to two days after the infusion. This color change is caused by the active ingredient and is generally described as normal, typically resolving within 48 hours.


Q: What is 'Hand-Foot Syndrome' and how common is it with Doxil?

Hand-Foot Syndrome, clinically known as palmar-plantar erythrodysesthesia (PPE), is listed in regulatory documents as a very common side effect. It is a skin reaction that may cause symptoms like redness, swelling, pain, tingling, or blistering specifically on the palms of the hands and the soles of the feet.


Q: Does Doxil have a lifetime cumulative dose limit?

Official documents cite that the risk of cardiomyopathy (heart muscle damage) is related to the total cumulative dose of anthracyclines received throughout a patient's lifetime. While a specific numeric limit for Doxil is not stated, this total exposure is an important consideration used in risk assessment by healthcare professionals.


Q: Can Doxil cause long-term heart problems or damage?

Yes, regulatory documents include a warning that the medicine is associated with a risk of potentially irreversible cardiomyopathy and congestive heart failure. This risk is a serious constraint, which is why mandatory cardiac monitoring is specified before, during, and after treatment.


Q: Is it possible to have an allergic reaction to the Doxil infusion?

Official labeling includes warnings for the possibility of serious, life-threatening, and sometimes fatal infusion-related reactions, including anaphylactoid reactions. These reactions are most often reported during the first administration of the medicine.


Q: What kind of infections are patients most at risk for while taking Doxil?

The primary infection risk comes from myelosuppression, which is a drop in the white blood cells. This condition, called neutropenia, can place patients at risk for developing a serious bacterial infection, such as sepsis.


Q: Is Doxil used to treat cancers other than ovarian and Kaposi's sarcoma?

Yes. According to official administration guidelines, the medicine is also indicated for the treatment of Multiple Myeloma in combination with another specific drug, in addition to Ovarian Cancer and AIDS-Related Kaposi’s Sarcoma.


Q: Can Doxil affect fertility in men or women?

As a cytotoxic agent, the active ingredient in Doxil is officially noted to be associated with potential effects on both male and female fertility. For this reason, patients of reproductive potential are advised in official documents to use effective contraception.


Q: What precautions should be taken regarding dental hygiene while on Doxil?

Since stomatitis/mucositis (inflammation and sores in the mouth) is a very common side effect, regulatory patient information often suggests using a soft toothbrush and avoiding vigorous cleaning. Patients are generally advised to discuss any planned major dental work with their healthcare professional.


Q: Why does Doxil sometimes cause a rash or skin irritation?

Skin reactions like Hand-Foot Syndrome are related to the specialized liposomal formulation. This design can lead to the active drug accumulating and leaking out of small blood vessels in the skin, particularly in areas like the palms and soles, causing inflammation.


Q: Can Doxil cause fatigue that lasts for several days after treatment?

Official documents list Fatigue and Asthenia (weakness) as very common side effects. While the exact duration varies by patient, regulatory patient information indicates that these effects may last for several days or potentially longer following an administration.


Q: Does Doxil work immediately, or does it take several cycles to see an effect?

Clinical studies evaluate the medicine's effect over time, with measurements of outcomes like Progression-Free Survival (PFS) and Objective Tumor Response Rate typically tracked over several cycles. The expected therapeutic effect is therefore evaluated over the course of multiple treatments, not instantaneously.


Q: Do side effects like nausea and vomiting happen with every Doxil treatment?

Nausea and vomiting are listed as very common adverse reactions. However, regulatory information indicates that the severity and the occurrence of these side effects can vary depending on factors such as the patient, the dose given, and the use of supportive medications.


Q: Are there any long-term follow-up requirements after finishing the full course of Doxil?

Yes. Due to the risk of delayed cardiotoxicity (heart damage), mandatory cardiac monitoring is often required to detect changes that may develop after the full course of treatment has been completed. This is especially important for patients with pre-existing heart risk factors.


Q: Does Doxil carry a risk of causing a secondary cancer later in life?

Official documents cite the risk of secondary malignancies, such as Acute Myelogenous Leukemia (AML), which is noted as a safety constraint associated with the class of drugs. This is noted as a long-term risk profile.


Q: Why is it important to report any signs of bleeding or unusual bruising?

Unexplained bleeding or unusual bruising is a key symptom to report because it can be a sign of thrombocytopenia (a low platelet count). This is a very common and potentially serious adverse reaction of the medicine.


Q: Is it normal to feel generally unwell for a few days after receiving Doxil?

Yes, a generalized feeling of being unwell (malaise) for a few days after treatment is consistent with the established safety profile. This is often related to the very common side effects of Fatigue, Asthenia (weakness), Nausea, and Fever.


Q: Is there any difference in how Doxil is used for ovarian cancer versus Kaposi's sarcoma?

Yes. Official administration guidelines indicate that there are differences in the protocol based on the condition being treated. Specifically, the recommended dose and the frequency of administration are different for these two conditions.


Q: How long after the infusion should I watch for side effects like fever or chills?

Infusion-related reactions may occur during or immediately following the infusion. However, signs of infection like fever and chills, which are related to low white blood cell counts, are typically watched for continuously, especially in the days after the infusion.

How should Doxil be stored and disposed of?

Doxil (pegylated liposomal doxorubicin) requires strict adherence to regulatory rules for storage and disposal to maintain the integrity of its specialized formulation and ensure safety.

Official Storage and Stability Requirements

Condition Regulatory Rule
Temperature Unopened vials must be stored under refrigeration at 2 C to 8 C (36 F to 46 F).
Light Vials must be stored in the original carton for protection from light.
Freezing The product must not be frozen.
Stability Once diluted for infusion, the solution is stable for 24 hours under refrigeration.
Child Safety Keep this medicine out of the sight and reach of children.

Handling and Disposal

Doxil is classified as a cytotoxic agent (a hazardous medicinal product). Consequently, any unused portions of the single-use vial, along with all materials used in its preparation and administration, must be discarded according to institutional and local special procedures for cytotoxic waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Doxil found in:

A-Z Index: